ESR1 and cancer: Lastly, the synergism demonstrated in the present study also suggests that disrupting the interaction between an ER co-activator - such as PPARGC1B - and ERα, or blocking their mutual activation, may represent a sensitive and leveraged strategy for cancer prevention [7].